<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The hallmark of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> by human herpesviruses, life-long persistence in the host, is unaffected by current antiviral therapies effective against replication of virus </plain></SENT>
<SENT sid="1" pm="."><plain>In vitro studies indicated that low concentrations of the <z:chebi fb="0" ids="26561">ribonucleotide</z:chebi> reductase inhibitor, <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi>, completely eliminated Epstein-Barr virus (EBV) episomes from latently infected Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell subsets, providing the first example of chemotherapeutic eradication of a latent herpesvirus from any cell population </plain></SENT>
<SENT sid="2" pm="."><plain>Unlike parental EBV-positive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells, virus-free cell progeny from one treated cell line no longer exhibited the malignant phenotype in tumorigenicity assays </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="44423">Hydroxyurea</z:chebi>-treated primary B lymphocytes immortalized by EBV ceased to proliferate as episomes were lost </plain></SENT>
<SENT sid="4" pm="."><plain>The altered growth phenotype of both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells and immortalized primary B cells suggests that latent EBV is an appropriate and accessible therapeutic target for treatment of some EBV-induced lymphoproliferations </plain></SENT>
</text></document>